What is the MOA of calcitonin gene-related peptide antagonists?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

What is the MOA of calcitonin gene-related peptide antagonists?

CGRP helps drive migraine by binding to its receptor on blood vessels and pain pathways, triggering vasodilation and nociceptive signaling. Antagonists work by blocking that interaction—either by binding the CGRP receptor itself or by interfering with the CGRP docking site—so CGRP cannot activate the receptor and downstream signaling is reduced. This interruption lessens migraine-related vasodilation and neuronal sensitization, which is why these drugs are effective. Other options target pathways not involved in CGRP signaling (dopamine receptors, COX-2, or beta-adrenergic receptors).

CGRP helps drive migraine by binding to its receptor on blood vessels and pain pathways, triggering vasodilation and nociceptive signaling. Antagonists work by blocking that interaction—either by binding the CGRP receptor itself or by interfering with the CGRP docking site—so CGRP cannot activate the receptor and downstream signaling is reduced. This interruption lessens migraine-related vasodilation and neuronal sensitization, which is why these drugs are effective. Other options target pathways not involved in CGRP signaling (dopamine receptors, COX-2, or beta-adrenergic receptors).

More practice questions